WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 135.14B |
| Revenue (ttm) | 21.98B |
| Net Income (ttm) | 4.60B |
| Shares Out | 4.07B |
| EPS (ttm) | 1.08 |
| PE Ratio | 30.65 |
| Forward PE | 24.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,009,005 |
| Average Volume | 53,733,764 |
| Open | 31.28 |
| Previous Close | 31.04 |
| Day's Range | 31.22 - 33.74 |
| 52-Week Range | 10.20 - 35.60 |
| Beta | 0.50 |
| RSI | 61.44 |
| Earnings Date | Aug 20, 2025 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact... [Read more]
Financial Performance
In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.
Financial numbers in CNY Financial StatementsNews
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a healthier future SHANGH...
WuXi Biologics Reports Solid 2025 Interim Results
Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net pro...
WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance ...
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stab...
WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
Earns CDP's highest rating for supply chain engagement on climate Adds to other CDP recognition—Water Security A List and leadership score on climate change Drives sustainability through value chain d...
WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years
WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expe...
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a health...
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation stabi...
Focus: China pharma projects disrupted by Sino-US tensions
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th...
Hong Kong stocks waver on China’s mixed economic data
Hong Kong stocks swung between gains and losses after China reported a mixed bag of economic data from May. The Hang Seng Index rose 0.1 per cent to 23,907.52 as of 10.23am local time. The Hang Seng T...
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L. It...
Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade
Hong Kong stocks jumped after a US court blocked President Donald Trump’s sweeping “reciprocal tariffs”, fuelling bets global trade tensions will ease. The Hang Seng Index rose 0.6 per cent to 23,385....
WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade)
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injecti...
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities Accele...
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI , April 22, 20...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou ...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site | WXXWY Stock News
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors- Proprietary process innovation reduces protein cost by nearly 7...
WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards
SHANGHAI , April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...
Wuxi Biologics ADR reports FY results
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million...
WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win
WuXi Biologics Celebrates Eighth Consecutive CDMO Leadership Award Win
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received ...
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and s...